For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

Our Lady of Lourdes Regional Medical Center is embracing cutting-edge technology to transform how heart conditions are ...

The study, recently published in the Journal of the American Heart Association, adds to a body of research dispelling the ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.